The US Court of Appeals for the Fifth Circuit upholds the FTC's decision in the first fully litigated reverse payment decision against generic pharmaceutical companies (Endo / Impax)

On April 13, the U.S. Court of Appeals for the Fifth Circuit affirmed the Federal Trade Commission's decision that Impax Laboratories entered an anticompetitive “reverse payment” settlement with…